Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 1.00 |
| ▸ | GBA1 | P04062 | 12/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064221 | 1.00 | SMPD1 (1.00) | SMPD1GBA1S1PR1S1PR3EPHX2 | |
| SCHEMBL25329590 | 1.00 | SMPD1 (1.00) | SMPD1GBA1S1PR1S1PR3EPHX2 | |
| SCHEMBL25329230 | 1.00 | SMPD1 (1.00) | SMPD1GBA1S1PR1S1PR3EPHX2 | |
| SCHEMBL23064315 | 1.00 | SMPD1 (1.00) | SMPD1GBA1S1PR1S1PR3EPHX2 | |
| SCHEMBL23064217 | 1.00 | SMPD1 (1.00) | SMPD1GBA1S1PR1S1PR3EPHX2 | |
| SCHEMBL23064212 | 1.00 | SMPD1 (1.00) | SMPD1GBA1S1PR1S1PR3EPHX2 | |
| Hydrochloric Acid SCHEMBL23064241 | 0.99 | SMPD1 (0.97) | SMPD1GBA1S1PR1S1PR3EPHX2 | |
| Hydrochloric Acid SCHEMBL29521395 | 0.99 | SMPD1 (0.97) | SMPD1GBA1S1PR1S1PR3EPHX2 | |
| SCHEMBL21641693 | 0.94 | SMPD1 (0.89) | SMPD1GBA1S1PR1S1PR3HRH4 | |
| SCHEMBL29520868 | 0.83 | SMPD1 (0.71) | SMPD1GBA1HRH4HRH3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4606373-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALOPECIA AREATA BY ACTING AS FUNCTIONAL INHIBITOR AGAINST S1PR1 AND S1PR4 | Nextgen Bioscience Co., Ltd. (KR) | 2025-08-27 | — | — | EP | claimed |
| CN-116669575-B | Use of triazole compounds as gastric somatostatin receptor agonists | 庆北大学校产学协力团 | 2025-04-04 | — | — | CN | claimed |
| EP-4496625-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | Nextgen Bioscience Co., Ltd. (KR) | 2025-01-29 | — | — | EP | claimed |
| CN-118234492-A | Pharmaceutical composition for preventing or treating alopecia areata with function of functional inhibitor for S1PR1 and S1PR4 | 次代生物科学株式会社 | 2024-06-21 | — | — | CN | claimed |
| US-20240148698-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALOPECIA AREATA ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-05-09 | — | — | US | claimed |
| WO-2024085417-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALOPECIA AREATA BY ACTING AS FUNCTIONAL INHIBITOR AGAINST S1PR1 AND S1PR4 | 주식회사 넥스트젠바이오사이언스 | 2024-04-25 | — | — | WO | claimed |
| US-11957665-B1 | Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1PR1 and S1PR4 | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-04-16 | — | — | US | claimed |
| US-20240041836-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2024-02-08 | — | — | US | claimed |
| CN-117396199-A | Pharmaceutical composition for preventing or treating inflammatory bowel disease as a functional antagonist of S1PR1 and S1PR4 | 次代生物科学株式会社 | 2024-01-12 | — | — | CN | claimed |
| WO-2023224362-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF RADIATION-INDUCED PULMONARY FIBROSIS, ACTING AS FUNCTIONAL ANTAGONIST OF S1PR1 AND S1PR4 | 주식회사 넥스트젠바이오사이언스 | 2023-11-23 | — | — | WO | claimed |
| US-20230339869-A1 | USE OF TRIAZOLE COMPOUND AS GHRELIN RECEPTOR AGONIST | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-10-26 | — | — | US | claimed |
| WO-2023182572-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | NEXTGEN BIOSCIENCE CO., LTD. (KR) | 2023-09-28 | — | — | WO | claimed |
| CN-116669575-A | Use of triazole compounds as gastric somatostatin receptor agonists | 庆北大学校产学协力团 | 2023-08-29 | — | — | CN | claimed |
| EP-4218757-A1 | USE OF TRIAZOLE COMPOUND AS GHRELIN RECEPTOR AGONIST | Kyungpook National University Industry-Academic Cooperation Foundation (KR) | 2023-08-02 | — | — | EP | claimed |
| WO-2023043024-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | NEXTGEN BIOSCIENCE (KR) | 2023-03-23 | — | — | WO | claimed |
| WO-2023042996-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | NEXTGEN BIOSCIENCE (KR) | 2023-03-23 | — | — | WO | claimed |
| EP-4714468-A1 | METHOD FOR ADMINISTERING MODULATOR TARGETING S1PR1 AND S1PR4 | Nextgen Bioscience Co., Ltd. (KR) | 2026-03-25 | — | — | EP | disclosed |
| US-12570617-B2 | Use of triazole compound as ghrelin receptor agonist | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-03-10 | — | — | US | disclosed |
| US-9724334-B1 | Method for treating a neurodegenerative disease or depression comprising administering derivatives of 2-amino-2-(1-dodecyl-1H-1,2,3-triazol-4-yl)propane-1,3-diol | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-08-08 | — | — | US | disclosed |
| US-9724334-B1 | Method for treating a neurodegenerative disease or depression comprising administering derivatives of 2-amino-2-(1-dodecyl-1H-1,2,3-triazol-4-yl)propane-1,3-diol | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041836-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | S1PR4, S1PR1, S1PR3 | SMPD1 16/4885GBA1 826/4885S1PR1 2/4885 |
| US-20240148698-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALOPECIA AREATA ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | S1PR5, S1PR4, S1PR1 | SMPD1 20/4885GBA1 1980/4885S1PR1 3/4885 |
| US-12570617-B2 | Use of triazole compound as ghrelin receptor agonist | GIPR, GLP1R, GCGR | SMPD1 4733/4885GBA1 4198/4885S1PR1 2774/4885 |
| US-20230339869-A1 | USE OF TRIAZOLE COMPOUND AS GHRELIN RECEPTOR AGONIST | GIPR, GPR119, GLP1R | SMPD1 4043/4885GBA1 3908/4885S1PR1 1181/4885 |
| US-11957665-B1 | Pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1PR1 and S1PR4 | S1PR4, S1PR5, S1PR1 | SMPD1 24/4885GBA1 1657/4885S1PR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.